The human immunodeficiency virus I (HIV-I) Vif protein influences the infectivity of HIV-1 in a cell type-specific manner (for reviews see Subbramanian & Cohen, 1994; Borman eta] ., 1995). Genotypically vif-defective virions [produced in so-called non-complementing or restrictive cells such as human peripheral blood mononuclear cells (PBMC), human primary monocyte-derived macrophages (MDM), H9 and some CEM sublines] are also phenotypically defective since they are unable to initiate a new round of infection, vif-Defective virions are blocked early in infection such that reverse transcription of viral RNA is inhibited at an intermediate stage (Subbramanian & Cohen, 1994 I995; Courcoul et al., 1995) . The HIV-1 Vif protein, I92 amino acids (aa) in size, is highly basic and is located in the cytoplasm (Michaels et al., 1993; Goncalves et al., 1994) . A fraction of Vif has been reported to associate with membranes, possibly indirectly, via clusters of basic amino acids in the extreme C terminus; an observation that has been correlated with Vif biological activity (Goncalves el al., 1994 (Goncalves el al., , 1995 . Here we report an in vivo selected vif gene product that is fully functional in HIV-1 infection of vif non-complementing cells despite a truncation of 19 C-terminal amino acids.
Detailed analysis (Wieland et al., 1994) of the in vivo genetic variability of vif, by direct sequencing of vifgenes amplified via PCR from 61 samples of uncultured PBMC from European HIV-l-positive patients, showed that the vif gene sequence varies considerably. A new subtype B HIV-1 Vif amino acid consensus sequence, with relatively few and short stretches of conserved amino acid positions was derived (named ConB*, Fig. la) . The method applied for sequence analysis allowed us to determine for each patient not only the predominant nucleotide (nt) at each position (on which ConB* is based; for details see Wieland et al., 1994) but also to detect minor nucleotide exchanges. This led to the interesting fnding that, although all of our 61 European samples harboured full-length vif ORFs, in 6 out of 61 isolates the respective vif gene populations additionally harboured individual sequences with defined premature stop codons at a relative abundance of ,-~ 20% (Wieland et al., 1994) . In 6 further European samples minor populations (< 20 %) with stop codons not previously reported have been identified, as is also the case in 3 out of 37 Ugandan samples from 18 HIV-l-positive patients (summarized in Fig. l b; U. Wieland, unpublished results). These observations have been confirmed in at least three independent PCR amplification and subsequent sequencing reactions and thus are unlikely to be due to PCR artefacts. While many of these vif genes containing translational stops will be defective, this may not apply in all cases. Importantly during in vivo replication, vif gene sequences may evolve which can compensate for mutations which would be defective in another context. In two of our European HIV patients, vif genes with premature stop codons leading to a deletion of the 19 C- Vif sequences previously analysed by us, including the predominant and full-length ORF sequences of patients A45 and A65 (Wieland et al., 1994) . Upper case letters refer to absolutely conserved residues; lower case letters refer to predominant amino acids at variable positions where only 'conservative' changes, that is from the same amino acid group (groups as previously described by Wieland et al., 1994) , have occurred ; lower case bold letters show the predominant aa at variable positions where 'non-conservative' changes have occurred; '?' indicates a variability above 25% at the respective position. The Vif amino acid sequence of pNL4-3 is shown in capital letters. In A45-2 and A65-5 several aa residues are shown in bold letters and marked by the symbols ~-or *. These residues belong to different aa groups (as previously described by Wieland et al., 1994) than the corresponding predominant aa in Con& ConB* or pNL4-3. Additionally, * indicates residues that occur at their respective position (mostly lower case bold type in ConB*) only in very few (less than 5%) of the 77 Vif sequences composing terminal amino acids (aa 174-192) have been found (Fig. 1) . This deletion overlaps with the longest stretch of absolutely conserved amino acids in HIV-1 subtype B Vif (aa 169-175, LTEDRWN, see Fig. 1 ).
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To address the question if the truncated but in vivo selected Vif protein would be functional or not, two patient-derived HIV-1 vif genes, shown in Fig. l(a) , were selected for cloning into the T cell-tropic infectious HIV-1 molecular proviral clone pNL4-3 B~l°env (called pNLBH here) (Bosch & Pawlita, 1990) which is a derivative of HIV NL4-3. One of the vif genes (vifA45-2) carries the above-mentioned premature stop codon (nt 520-522; TGA instead of TGG in the full-length wild-type virus) deleting aa 174-192. The other isolate (vifA65-5) represents a full-length vif ORF, but contains several of the same rare amino acid exchanges as vifA45-2 and served as a control.
Nested PCR from patients' uncultured PBMC extracts was essentially performed as previously described (Wieland et aI., 1994) with primers El/E2 and I1/I2" (I2" 5' GCAGTTGTTGCAGAATTCTTATT 3', pNL4-3 nt 5760-5738 (Myers et al., 1994) ). The internal PCR products I1/I2" from both patients were digested with BspMl (cuts after vif nt 7; pNL nt 5046) and EcoRI (pNL nt 5743) and, via a subcloning step, were inserted into pNLBH to create the HIV-1 proviral clones A45-2 and A65-5. Thus in summary, in A45-2 and A65-5, 696 bp of pNLBH from vif nt 8 to 124 nt after the vif stop codon, were exchanged for patient-derived sequences.
To initiate virus production, the two recombinant proviruses A45-2 and A65-5, pNLBH and a vif-defective derivative thereof (see below) were transfected into COS cells (Wilk et al., 1992) which were then cocultivated with (vifcomplementing) MT-4 cells for 48 h. Infected MT-4 cells were further propagated for 5 days (then 100 % infected) to produce high-titre virus stocks. Following normalization of filtered virus stocks for their p24 content by ELISA (Organon Teknica), two different amounts (450 ng p24 or 45 ng p24, respectively) of pNLBH or recombinant virions were used to infect either MT-4 cells (5 x 105) or vif-non-complementing H9 cells (5 x 105) and activated human PBMC [2 x 106; freshly prepared 4 days prior to infection and cultured in the presence of PHA (day 1-2) and interleukin-2 (IL-2) to stimulate T cell blast formation (Poli & Fauci, 1991) ]. Monitoring of the viral p24 antigen released into the cell culture supematants (Fig. 2a) clearly demonstrated that the virus A45-2 encoding the truncated patient-derived Vif protein was fully infectious not only in MT-4 cells but also in vif-non-complementing activated PBMC and H9 cells. The same was true for A65-5. In contrast, derivatives of pNLBH defective in vif, containing either a 2 nt or a 28 nt linker insertion at the NdeI site (pNL4-3 nt position 5123) and named pNLBHvif-and pNLBHvifL, respectively, replicated with normal kinetics in MT-4 cells, but were restricted to one round of replication in H9 cells and activated PBMC (Fig. 2a, pNLBHvifL not shown) . The courses of infection were confirmed by anti-HIV-immunofluorescence staining (Bosch & Pawlita, 1990) (Fig. 2 b) , demonstrating that at a given time point post-infection (p.i.) similar percentages of MT-4 cells or H9 cells, respectively, were infected with the three respective viruses. The continued presence of the respective variant vif gene sequences, including the premature stop codon, was unambiguously confirmed by PCR DNA sequencing of the entire proviral vif ORF in all cultures at days 6 and 11 p.i. (data not shown). Both VifA45-2 and VifA65-5 contain a non-conservative amino acid substitution (K91 ~ E) in the first Vif antigenic domain (aa 87-94) (Wieland et al., 1991) and in Vif45-2, additionally 5 out of 7 aa of the major, second antigenic domain (aa 172-179) are missing. This is presumably the reason why the truncated VifA45-2 was not detected at all and VifA65-5 was detected less strongly (although unambiguously in comparison to wild-type Vif) in Western blot analysis employing a whole set of anti-Vif sera (data not shown), including those described by Garret et al. (1991) , Goncalves et al. (1994) and Wieland et al. (1991) . However, the fact that A45-2 virions with confirmed vif variant sequences were fully infectious in non-permissive H9 cells and PBMC clearly demonstrates that the 19 C-terminal aa of Vif are dispensable for function in T cell culture.
Macrophages also represent an important reservoir for HIV-1 in natural infection and have been described as nonpermissive for the replication of vif-defective macrophagetropic HIV-1 in vitro (Gabuzda et al., 1994; Kawamura et al., 1994) . We thus examined the replicative phenotype of A45-2 virions produced in and released from human primary MDM in vitro. Since A45-2 is expected to display T cell-tropism due to its env gene from HIV strain BH10 (Myers et al., 1994; Freed & Martin, 1994) , we initiated virus production in MDM by applying the technique of microinjection of proviral DNA (Sczakiel et al., 1993) . MDM were prepared from peripheral blood by 5 day adherence to glass cover-slips essentially as described (Perno & Yarchoan, 1991 and references therein) and were cultured for a total of 9 days prior to microinjection to allow full adherence and differentiation. Cells were grown in the presence of recombinant granulocyte/macrophage colonystimulating factor (GM-CSF) (I00 U/ml RPMI) since this cytokine has been reported to enhance viral expression in this primary cell system (Perno & Yarchoan, 1991 therein). Only mature, adherent MDM were selected for injection of proviral DNA (10 ng/pl) from pNLBH, A45-2, or pNLBHvifL into the nucleus essentially as described before (Sczakiel et al., 1993) . The assay was performed in quadruplicate on separate cover-slips, with 50 injected cells each. Cover-slips were transferred to multiwell culture plates, and two samples were overlaid with I x 105-2 x 105 MT-4 cells at day 3 or 8 post-microinjection (p.m.i.), respectively. The spread of viral infections was monitored by anti-HIV-immunofluorescence of methanol-acetone-fixed MT-4 cells from the cocultures. In contrast to pNLBHvifL, with A45-2 and pNLBH, HIV-1-positive MT-4 cells were observed as soon as 4-7 days after cocultivation and infection reached 100% around day 11-13. The kinetics of viral spread were very similar for both viruses. When primary macrophages were microinjected with pNLBHvifL, no productive infection of cocultured MT-4 cells with vif-defective virus could be detected. These results show that A45-2-virions released from primary MDM are fully replication competent despite the truncation of the C terminus. Using a computer-aided search employing the PROSITE library (Bairoch, 1992) , only six putative phosphorylation sites in Vif were revealed, of which only one [a protein kinase C (PKC) motif] was considered to be a good candidate for functionality since the residue to be phosphorylated ($32) was absolutely conserved and the overall motif matched the PKC consensus pattern [(S,T)X(R,K)] sufficiently well. Since the existence of putative phosphorylation sites has been reported previously (Sova et al., 1995) (Fig. 3 b) . On the other hand, although Vif expression could be clearly demonstrated after metabolic labelling with [a~S]methionine, no Vifspecific band was detected in the phosphorylation assay (Fig.  3 a) . Thus, our findings provide no evidence that Vif might be phosphorylated under the experimental conditions employed. In summary, the results presented in this study show that in the context of the in vivo variant Vif45-2, the C-terminal 19 aa of the Vif protein are dispensable for its function in the cells tested. The variant stop codon at position 174 affects a stretch of absolutely conserved amino acids (positions 169-175) and also results in the removal of four of a cluster of five basic amino acids (at positions 173, 176, 179, 181 and 184) at the C terminus of Vif. Goncalves et al. (1994) have reported on a significant loss of function after deletion of the C-terminal 22 aa of Vif. Furthermore, in a very recent report, the same authors showed that the substitution of certain of the basic amino acids within the C-terminal region resulted in a severe reduction in infectivity (Goncalves et al., 1995) . These losses in function correlated with the ability of Vif to associate with membranes and has led to the proposal that membrane binding is mediated by the C-terminal region and is a prerequisite for Vif function. The results presented in this paper, using Vif with a somewhat shorter truncation and infectivity as a measure of function, do not support this hypothesis. In contrast to in vitro mutagenesis, which has the drawback that introduced exchanges can affect overall protein structure, the variant described here has 'evolved' in vivo. The fact that it has retained function is positive evidence for the C-terminal 19 aa being dispensable for Vif function in the cells tested. In general, analysis of in vivo selected, patient-derived Vif variants may yield information, not attainable through in vitro mutagenesis, as to the importance of putative functional domains of the Vif protein.
In this context it is of interest that in a recent analysis of vif sequences from Ugandan HIV-l-positive patients, in three serial samples from one patient, 100 % of the vifgene sequences contained an in-frame deletion of 6 nt, deleting aa 185-186 (U. Wieland, unpublished results).
